Apple
AAPL
Cisco
CSCO
Disney
DIS
4
Qualcomm
QCOM
5
Taiwan Semiconductor
TSM
US Stock MarketDetailed Quotes
URGN UroGen Pharma Ltd
- 11.060
- -0.140-1.25%
Close Mar 31 16:00 ET
- 11.060
- 0.0000.00%
Post 16:36 ET
509.80MMarket Cap-3.74P/E (TTM)
11.158High10.590Low602.86KVolume10.880Open11.200Pre Close6.61MTurnover1.63%Turnover RatioLossP/E (Static)46.09MShares20.70052wk High-57.91P/B409.14MFloat Cap9.03052wk Low--Dividend TTM36.99MShs Float69.568Historical High--Div YieldTTM5.07%Amplitude4.850Historical Low10.960Avg Price1Lot Size
Market Insights
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
UroGen Pharma Ltd Stock Forum
UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102
UroGen's Major Pipeline Play: Revolutionary Cancer-Fighting Virus Acquisition Reshapes Growth Strategy
Breakthrough Bladder Cancer Treatment Achieves 83% Response Rate, FDA Decision Coming 2025
Clinical Trial Results: Cancer Drug Maintains Response for Nearly 4 Years, Surpassing Expectations
UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
• Kaplan-Meier Estimate of Duration of Response at 12 Months in Patients Who Achieved a Complete Response at Three Months was 82.3% (95% CI, 75.9%, 87.1%)
• Side Effect Profile Consistent with Previous Clinical Trials of UGN-102
• UroGen will Host a Virt...
No comment yet